Hims & Hers Health, Inc. (NYSE:HIMS) Receives Consensus Recommendation of "Hold" from Brokerages

Key Points

• Analysts maintain a “Hold” consensus on Hims & Hers Health, with 11 hold, four buy and one sell rating among 16 brokerages. The average 12-month price target is $32.50.
• The company reported 38.2% year-over-year revenue growth to $753.2 million, exceeding expectations, but missed earnings estimates substantially and remained unprofitable.
• Growth opportunities from expansion into Australia and the company’s weight-loss business are offset by regulatory and legal risks, including FDA scrutiny of unapproved weight-loss drugs and allegations involving data privacy, advertising and billing practices.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) has received an average recommendation of "Hold" from the sixteen brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eleven have assigned a hold recommendation and four have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $32.50.

A number of brokerages have recently weighed in on HIMS. JPMorgan Chase & Co. dropped their target price on Hims & Hers Health from $35.00 to $33.00 and set an "overweight" rating on the stock in a report on Tuesday, May 12th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Wall Street Zen upgraded shares of Hims & Hers Health from a "sell" rating to a "hold" rating in a research note on Saturday, August 15th. Zacks Research upgraded shares of Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research report on Monday, July 13th. Finally, Jefferies Financial Group set a $24.50 price target on shares of Hims & Hers Health in a report on Tuesday, May 12th.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers launched its Hims brand in Australia following its acquisition of Eucalyptus, marking its first Asia-Pacific expansion. The move broadens the company’s addressable market and adds potential international revenue growth, though execution and integration remain important. Hims Enters Australia, Marking First Expansion into the Asia-Pacific Market
• Positive Sentiment: An optimistic analyst view described Hims & Hers as a scalable consumer-health platform, citing 38% revenue growth, strong quarterly guidance and multiple product lines exceeding $100 million in annual recurring revenue. The report nonetheless noted margin pressure from branded weight-loss products and international expansion. Hims & Hers: A Healthcare Behemoth In The Making
• Neutral Sentiment: Several firms announced investigations or reminders about a pending securities class action, with a November 2, 2026 deadline for investors seeking lead-plaintiff status. These announcements largely repeat existing allegations and do not represent court findings. HIMS Deadline Alert
• Negative Sentiment: The FDA warned telehealth companies and compounding pharmacies about marketing or using unapproved weight-loss drugs, including retatrutide and cagrilintide. Because weight-loss treatments are a major growth area for Hims & Hers, investors may fear tighter compliance requirements, product restrictions and slower growth. Hims & Hers falls after FDA crackdown on unapproved weight-loss drugs
• Negative Sentiment: Legal complaints and board investigations allege that Hims & Hers shared protected health information with advertisers, used deceptive advertising or billing practices, and made subscription cancellations difficult. Potential litigation costs, regulatory consequences and reputational damage are the principal stock risks. Stockholder Alert

Hims & Hers Health Price Performance

NYSE HIMS opened at $28.45 on Wednesday. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21. Hims & Hers Health has a 1 year low of $13.74 and a 1 year high of $65.30. The company has a market cap of $6.64 billion, a PE ratio of -45.16 and a beta of 2.42. The stock's 50-day moving average price is $31.97 and its two-hundred day moving average price is $26.57.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.32). The business had revenue of $753.21 million for the quarter, compared to analysts' expectations of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business's quarterly revenue was up 38.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.17 EPS.

Insider Buying and Selling at Hims & Hers Health

In related news, COO Michael Chi sold 14,027 shares of the business's stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the sale, the chief operating officer owned 432,124 shares of the company's stock, valued at approximately $13,611,906. The trade was a 3.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Oluyemi Okupe sold 4,938 shares of the stock in a transaction that occurred on Wednesday, August 19th. The stock was sold at an average price of $29.99, for a total value of $148,090.62. Following the completion of the transaction, the chief financial officer owned 264,117 shares in the company, valued at $7,920,868.83. This represents a 1.84% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 186,769 shares of company stock worth $6,035,648 over the last quarter. Insiders own 11.76% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of HIMS. Cunning Capital Partners LP bought a new stake in Hims & Hers Health in the fourth quarter worth $1,110,000. Norges Bank bought a new position in Hims & Hers Health during the fourth quarter valued at about $62,153,000. Virtu Financial LLC bought a new position in Hims & Hers Health during the fourth quarter valued at about $1,937,000. Louisiana State Employees Retirement System acquired a new stake in shares of Hims & Hers Health in the first quarter worth about $1,254,000. Finally, Clear Street Group Inc. lifted its position in shares of Hims & Hers Health by 23.6% in the fourth quarter. Clear Street Group Inc. now owns 1,904,294 shares of the company's stock worth $61,832,000 after buying an additional 363,893 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients' doorsteps.

The company's product portfolio addresses key areas of men's and women's health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source